WO2005000203A3 - Methods for treating cognitive impairment and improving cognition - Google Patents

Methods for treating cognitive impairment and improving cognition Download PDF

Info

Publication number
WO2005000203A3
WO2005000203A3 PCT/US2004/015974 US2004015974W WO2005000203A3 WO 2005000203 A3 WO2005000203 A3 WO 2005000203A3 US 2004015974 W US2004015974 W US 2004015974W WO 2005000203 A3 WO2005000203 A3 WO 2005000203A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cognitive impairment
treating cognitive
improving cognition
cognition
Prior art date
Application number
PCT/US2004/015974
Other languages
French (fr)
Other versions
WO2005000203A2 (en
Inventor
Mel H Epstein
Kjesten A Wiig
Randall C Carpenter
H Moore Arnold
Original Assignee
Sention Inc
Mel H Epstein
Kjesten A Wiig
Randall C Carpenter
H Moore Arnold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/139,606 external-priority patent/US20030119884A1/en
Priority claimed from US10/444,970 external-priority patent/US20030232890A1/en
Priority claimed from US10/791,223 external-priority patent/US20050059743A1/en
Priority to US10/557,095 priority Critical patent/US20070117869A1/en
Priority to CN2004800211168A priority patent/CN1826105B/en
Priority to CA002567746A priority patent/CA2567746A1/en
Priority to JP2006533278A priority patent/JP2007502863A/en
Priority to AU2004251596A priority patent/AU2004251596B2/en
Priority to EP04752902.9A priority patent/EP1635851B1/en
Priority to MXPA05012614A priority patent/MXPA05012614A/en
Application filed by Sention Inc, Mel H Epstein, Kjesten A Wiig, Randall C Carpenter, H Moore Arnold filed Critical Sention Inc
Publication of WO2005000203A2 publication Critical patent/WO2005000203A2/en
Priority to US11/133,144 priority patent/US7619005B2/en
Publication of WO2005000203A3 publication Critical patent/WO2005000203A3/en
Priority to US11/636,703 priority patent/US20070197663A1/en
Priority to US11/636,702 priority patent/US20070100000A1/en
Priority to US11/636,644 priority patent/US20070099999A1/en
Priority to AU2008202794A priority patent/AU2008202794A1/en
Priority to US12/221,776 priority patent/US20100022658A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cognitive impairments are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an I-amphetamine compound. In another embodiment, the method includes administering an 1-methamphetamine compound.
PCT/US2004/015974 2000-11-01 2004-05-21 Methods for treating cognitive impairment and improving cognition WO2005000203A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US10/557,095 US20070117869A1 (en) 2000-11-01 2004-05-21 Methods for treating coginitive impairment and improving cognition
CN2004800211168A CN1826105B (en) 2003-05-23 2004-05-21 Use of amphetamine composition in producing medicine for treating cognitive impairment
CA002567746A CA2567746A1 (en) 2003-05-23 2004-05-21 Methods for treating cognitive impairment and improving cognition
JP2006533278A JP2007502863A (en) 2003-05-23 2004-05-21 Methods for treating and improving cognitive impairment
AU2004251596A AU2004251596B2 (en) 2003-05-23 2004-05-21 Methods for treating cognitive impairment and improving cognition
EP04752902.9A EP1635851B1 (en) 2003-05-23 2004-05-21 Methods for treating cognitive impairment and improving cognition
MXPA05012614A MXPA05012614A (en) 2003-05-23 2004-05-21 Methods for treating cognitive impairment and improving cognition.
US11/133,144 US7619005B2 (en) 2000-11-01 2005-05-19 Methods for treating cognitive impairment in humans with Multiple Sclerosis
US11/636,644 US20070099999A1 (en) 2000-11-01 2006-12-08 Methods of treating depression
US11/636,702 US20070100000A1 (en) 2000-11-01 2006-12-08 Methods of providing neuroprotection
US11/636,703 US20070197663A1 (en) 2000-11-01 2006-12-08 Methods of treating memory and cognitive impairments in humans following stroke and traumatic brain injury
AU2008202794A AU2008202794A1 (en) 2003-05-23 2008-06-24 Methods for treating cognitive impairment and improving cognition
US12/221,776 US20100022658A1 (en) 2000-11-01 2008-08-06 Methods for treating cognitive impairment in humans

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US37400101A 2001-10-31 2001-10-31
US10/139,606 US20030119884A1 (en) 2000-11-01 2002-05-02 Methods and compositions for regulating memory consolidation
US47316803P 2003-05-23 2003-05-23
US10/444,970 US20030232890A1 (en) 2000-11-01 2003-05-23 Methods for treating an impairment in memory consolidation
US10/444,970 2003-05-23
US60/473,168 2003-05-23
US10/791,223 US20050059743A1 (en) 2000-11-01 2004-03-02 Methods for treating mild cognitive impairment and alzheimer's disease
US10/791,223 2004-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/791,223 Continuation-In-Part US20050059743A1 (en) 2000-11-01 2004-03-02 Methods for treating mild cognitive impairment and alzheimer's disease

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/133,144 Continuation-In-Part US7619005B2 (en) 2000-11-01 2005-05-19 Methods for treating cognitive impairment in humans with Multiple Sclerosis
US11/636,702 Continuation US20070100000A1 (en) 2000-11-01 2006-12-08 Methods of providing neuroprotection
US11/636,644 Continuation US20070099999A1 (en) 2000-11-01 2006-12-08 Methods of treating depression
US11/636,703 Continuation US20070197663A1 (en) 2000-11-01 2006-12-08 Methods of treating memory and cognitive impairments in humans following stroke and traumatic brain injury

Publications (2)

Publication Number Publication Date
WO2005000203A2 WO2005000203A2 (en) 2005-01-06
WO2005000203A3 true WO2005000203A3 (en) 2005-12-29

Family

ID=33556727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015974 WO2005000203A2 (en) 2000-11-01 2004-05-21 Methods for treating cognitive impairment and improving cognition

Country Status (1)

Country Link
WO (1) WO2005000203A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871772B2 (en) 2008-05-27 2014-10-28 Ampio Pharmaceuticals, Inc. Therapeutic methods and compounds

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5271540B2 (en) 2005-01-20 2013-08-21 インスティチュート フォー モレキュラー メディスン インコーポレイテッド Therapeutic agents and pharmaceutical compositions containing methylphenidate derivatives
US20110105621A1 (en) * 2006-08-23 2011-05-05 The University Of Montana Method of reducing brain cell damage, inflammation or death
BRPI0715633A2 (en) * 2006-08-23 2013-07-02 Univ Montana Neuronal Cell Damage Reduction Method
US20140107140A1 (en) * 2011-06-24 2014-04-17 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of gulf war illness
EP2723448B1 (en) * 2011-06-24 2017-04-12 K-Pax Pharmaceuticals, Inc. Compositions for the treatment of chronic fatigue
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151449A (en) * 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
US6492427B2 (en) * 1998-10-09 2002-12-10 L. Sai Latha Shankar Methods for treating multiple sclerosis
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
HU207280B (en) 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
GB9928630D0 (en) 1999-12-04 2000-02-02 Dunlop Tyres Ltd Motor-cycle radial tyre

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151449A (en) * 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
US6492427B2 (en) * 1998-10-09 2002-12-10 L. Sai Latha Shankar Methods for treating multiple sclerosis
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1635851A4 *
YASAR ET AL: "Are Metabolites of L-Deprenyl (Selegiline) Useful or Harmful? Indications from Preclinical Research.", J NEURAL TRANSM., vol. 48, 1996, pages 61 - 73, XP008020416 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871772B2 (en) 2008-05-27 2014-10-28 Ampio Pharmaceuticals, Inc. Therapeutic methods and compounds
US9522893B2 (en) 2008-05-27 2016-12-20 Ampio Pharmaceuticals, Inc. Therapeutic methods and compounds

Also Published As

Publication number Publication date
WO2005000203A2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2001000245A3 (en) HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
PL397846A1 (en) Treatment of disorders associated with TNFα
AU2002254158A1 (en) Medical devices, compositions and methods for treating vulnerable plaque
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
AU7964200A (en) Asymmetric organic peroxide, crosslinking agent comprising the same, and method of crosslinking with the same
TR199802676A3 (en) Method for the treatment and prevention of tumors, tumor-related diseases and cachexia.
ZA200203253B (en) Methods and kits for treating depression or preventing deterioration of cognitive function.
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
AU2002323270A1 (en) Composition and method for treating hiv infection
AU2002332224A1 (en) Arrangement and method for electrochemical purification or treatment
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2005000203A3 (en) Methods for treating cognitive impairment and improving cognition
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
AU2002349264A1 (en) Method for the preparation, treatment and updating tool data
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
AP2004003070A0 (en) The method of treating cancer.
AU2002324753A1 (en) Composition and method for treating viral infection
AU2002365168A1 (en) Method and composition for treating and preventing hiv infection and aids
AU2001228834A1 (en) Metal part, and surface treating method therefor
AU2002340557A1 (en) Bipolar transistor and method for producing the same
WO2003017817A3 (en) Diagnosis, prevention and treatment of cancer
WO2003059332A3 (en) Use of an anti-microtubule agent for the treatment of uveitis
WO2003093948A3 (en) Dynamic human resources knowledge base and process
AU2002365941A1 (en) Methods of diagnosis, monitoring and treatment of fertility
WO2000048584A3 (en) Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480021116.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11133144

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006533278

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012614

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 543759

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004251596

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004752902

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004251596

Country of ref document: AU

Date of ref document: 20040521

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004251596

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007117869

Country of ref document: US

Ref document number: 10557095

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004752902

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11133144

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2567746

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 10557095

Country of ref document: US